Summary of base-case analyses
| Rezvilutamide plus ADT | Bicalutamide plus ADT | Incremental | |
| Total cost (US$) | 106 807.74 | 46 048.92 | 60 758.82 |
| Drug cost | 79 345.08 | 16 148.68 | 63 196.40 |
| AEs management cost | 56.05 | 55.91 | 0.14 |
| Disease management cost | 4749.11 | 2410.63 | 2338.48 |
| Subsequent treatment cost | 22 609.64 | 27 433.69 | −4824.26 |
| QALYs | 6.08 | 3.80 | 2.28 |
| ICER (US$/QALY) | 26 656.94 | ||
ADT, androgen deprivation therapy; AEs, adverse events; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.